Partner Headlines - BMRN

  1. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga
  2. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga
  3. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  4. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' ...

    Benzinga
  5. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  6. BIOMARIN PHARMA

    IBD
  7. State Of The Union Lights Up Biotech

    Benzinga
  8. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  9. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  10. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  11. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  12. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  13. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  14. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  15. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  16. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  17. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  18. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  19. BioMarin buying Prosensa

    IBD
  20. Trio Of Major Deals Disclosed

    IBD
  21. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  22. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  23. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  24. Benzinga's Volume Movers

    Benzinga
  25. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  26. Stocks Hitting 52-Week Highs

    Benzinga
  27. Morning Market Movers

    Benzinga
  28. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  29. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  30. Benzinga's Top #PreMarket Gainers

    Benzinga
  31. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  32. Stocks Hitting 52-Week Highs

    Benzinga
  33. Benzinga's Top Upgrades

    Benzinga
  34. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  35. BioMarin Weathers The Storm

    Benzinga
  36. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  37. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  38. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  39. Benzinga's Top Upgrades

    Benzinga
  40. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  41. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  42. Top Trending Tickers On StockTwits For February 18

    Benzinga
  43. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  44. You Can No Longer Ignore Biotech

    GuruFocus
  45. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  46. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  47. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  48. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  49. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  50. Benzinga's Top #PreMarket Gainers

    Benzinga
  51. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  52. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  53. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  54. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  55. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  56. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  57. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  58. Roche

    IBD
  59. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  60. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  61. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  62. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  63. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  64. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  65. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  66. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  67. Benzinga's Volume Movers

    Benzinga
  68. Benzinga's Top Pre-Market Gainers

    Benzinga
  69. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  70. Benzinga's Top Pre-Market Gainers

    Benzinga
  71. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    Benzinga
  72. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  73. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  74. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  75. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
  76. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  77. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  78. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin ...

    Benzinga
  79. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  80. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  81. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  82. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  83. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  84. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral ...

    Benzinga
  85. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  86. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga
  87. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  88. Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

    GuruFocus
  89. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  90. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  91. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  92. Myriad Genetics Stock Hits High On Earnings Beat

    IBD
  93. Highs & Lows: BioMarin Pharmaceutical, Best Buy, and Skullcandy

    SchaeffersResearch
  94. BioMarin soars on drug data

    IBD
  95. Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

    Benzinga
  96. UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin Pharmaceutical ...

    Benzinga
  97. Mid Morning Market Update: Markets Decline, Stifel Financial ...

    Benzinga
  98. Stocks Hitting 52-Week Highs

    Benzinga
  99. BioMarin Stock Soars On Positive Drug Data

    IBD
  100. BioMarin Phase 3 Study of GALNS Meets Primary Endpoint

    Benzinga
Trading Center